Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ACR-2316-101: Phase 1/2 Study of ACR-2316 in Subjects With Advanced Solid Tumors

NCT06667141 is registered in ClinicalTrials.gov with Acrivon Therapeutics as lead sponsor.

NCT NCT06667141
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06667141 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ACR-2316-101: Phase 1/2 Study of ACR-2316 in Subjects With Advanced Solid Tumors
Lead sponsor
Acrivon Therapeutics
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 8, 2024
Completion date
December 12, 2027
Enrollment
100 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

specific advanced solid tumors